The inaugural edition of Premier Voices focuses on rare oncology drug development and takes a looks at:
* Using adaptive design to limit patient exposure to ineffective treatments and increase the overall likelihood of success
* Making the most of small and geographically dispersed patient populations
* Dealing with limitations such as a lack of defined biomarkers and baseline standard-of-care therapies
* Finding out what Dr. Colin Hayward, our chief medical officer, would be doing if he weren’t working in clinical development!